Company Profile
Kronos Bio Stock Price, News & Catalysts
- Ticker:
- KRON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for KRON.
Company overview
Business overview
Kronos Bio was an oncology company focused on epigenetic and transcriptional regulation in cancer before its restructuring and public-market decline. Its story centered on chromatin biology and targeted cancer therapy.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, Kronos sat in oncology biotechnology.
Business Model Characteristics
The business depended on clinical data, target validation, and the ability to convert epigenetic science into therapeutic value.
Position Within the Biotechnology Landscape
Kronos belongs to the historical oncology-biotech set rather than the current live public-company universe.
Future catalysts
- Kronos is now mostly a legacy / closeout story, so the catalysts are transaction or asset-resolution updates rather than fresh pipeline milestones. The market no longer treats it like an active growth name.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Kronos Bio do?
Kronos Bio was an oncology company focused on epigenetic and transcriptional regulation in cancer before its restructuring and public-market decline. Its story centered on chromatin biology and targeted cancer therapy.
On which exchange is KRON stock listed?
Kronos Bio (KRON) is associated with NASDAQ, United States, Biopharma.
What is Kronos?
Kronos is now mostly a legacy / closeout story, so the catalysts are transaction or asset-resolution updates rather than fresh pipeline milestones.
Which conditions is Kronos Bio targeting with Kronos?
Kronos Bio is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Kronos Bio describe recent progress with Kronos?
Kronos is now mostly a legacy / closeout story, so the catalysts are transaction or asset-resolution updates rather than fresh pipeline milestones.
What future catalysts are investors watching for Kronos Bio?
Kronos is now mostly a legacy / closeout story, so the catalysts are transaction or asset-resolution updates rather than fresh pipeline milestones. The market no longer treats it like an active growth name.